triLift™ honored as the “Best Non-Invasive Facelifting Device” and the “Best Light & Energy-Based Device” categories for its breakthrough technology in facial muscle stimulation. Renowned awards program celebrates excellence in aesthetics as chosen by industry professionals and readers.
Lumenis’s OptiPLUS Delivers Clinically Significant Results for DED
Ray Corbin-Simon, OD, shares how OptiLIGHT and OptiPLUS have elevated her eye care practice by addressing her patients’ various needs.
The 2024 IPL Report
Discover why OptiLIGHT stands out in the latest 2024 IPL Report! See how over 500 optometrists are using IPL to treat dry eye disease, improve patient outcomes, and overcome treatment challenges. Uncover the benefits, ROI, and why OptiLIGHT is a top choice for Dry Dye Disease management due to MGD!
Teaching Peers About Dry Eye Disease Boosts Patients’ Access to Care
Press PublicationsDry Eye Teaching Peers About Dry Eye Disease Boosts Patients’ Access to Care May 7, 2024 Pamela E. Theriot, OD, FAAO Dry Eye Relief Center at Lusk Eye Specialists
Discussing DED treatment cost can help build trust and lead to more same-day procedures
Discussing DED treatment cost can help build trust and lead to more same-day procedures November 28, 2023 Cory Lappin, OD shares his strategies for getting comfortable with talking treatment costs
Response of tear cytokines following intense pulsed light combined with meibomian gland expression for treating meibomian gland dysfunction-related dry eye
Researchers found that 20 tear cytokines decreased significantly after IPL treatment, illustrating how IPL suppresses DED’s vicious cycle of inflammation.
Light After the Storm: A Hopeful Look Ahead for Dry Eye Disease
Dr. Laura M. Periman explains the multifactorial complexity of dry eye disease—and how OptiLight is helping the future look bright.
Fishman et al (2020): Real-Time Video Microscopy of In Vitro Demodex Death by Intense Pulsed Light
An in-vitro study demonstrated that, with settings used for treatment of dry eye due to meibomian gland dysfunction (MGD), Lumenis IPL with OPTTM destroyed an isolated Demodex mite.
Choi et al (2019): Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines
In a prospective, single arm study, Lumenis IPL with OPT™ improved signs and symptoms of Dry Eye Disease due to MGD, and decreased tear levels of key inflammation markers. The decrease of two of these markers were correlated with improvement in meibum expressibility.
Arita et al. (2019): Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dsyfunction
The results of a prospective, random control trial show the combination of Lumenis IPL with OPT™ and Meibomian Gland Expression (MGX) improves tear film homeostasis and ameliorates ocular symptoms in patients with refractory Meibomian Gland Dysfunction (MGD).